J&J receives subpoena for Natrecor marketing documents
Executive Summary
The Boston U.S. Attorney's office issues subpoena to Johnson & Johnson subsidiary Scios requesting documents related to the sales and marketing of its congestive heart failure drug Natrecor (nesiritide), the company announced July 20. The subpoena comes on the heels of a New England Journal of Medicine article by Eric Topol (Cleveland Clinic) asserting that Scios has conducted an "aggressive marketing campaign" to promote Natrecor for serial outpatient use (1"The Pink Sheet" July 18, 2005, p. 9)...